Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics

Elderly patients with AML ineligible for induction have a dismal prognosis; hence disease stabilization is a primary treatment goal. This case of a 75-year-old patient with secondary AML receiving the combination of decitabine and ATRA (within the DECIDER trial, NCT00867672) demonstrates an above-av...

Descripción completa

Detalles Bibliográficos
Autores principales: Javorniczky, Nora Rebeka, Grishina, Olga, Hund, Inga, Pantic, Milena, Pfeifer, Dietmar, Schmoor, Claudia, Thomas, Johanna, Duyster, Justus, Becker, Heiko, Lübbert, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683313/
https://www.ncbi.nlm.nih.gov/pubmed/38012682
http://dx.doi.org/10.1186/s13148-023-01596-5
_version_ 1785151168178028544
author Javorniczky, Nora Rebeka
Grishina, Olga
Hund, Inga
Pantic, Milena
Pfeifer, Dietmar
Schmoor, Claudia
Thomas, Johanna
Duyster, Justus
Becker, Heiko
Lübbert, Michael
author_facet Javorniczky, Nora Rebeka
Grishina, Olga
Hund, Inga
Pantic, Milena
Pfeifer, Dietmar
Schmoor, Claudia
Thomas, Johanna
Duyster, Justus
Becker, Heiko
Lübbert, Michael
author_sort Javorniczky, Nora Rebeka
collection PubMed
description Elderly patients with AML ineligible for induction have a dismal prognosis; hence disease stabilization is a primary treatment goal. This case of a 75-year-old patient with secondary AML receiving the combination of decitabine and ATRA (within the DECIDER trial, NCT00867672) demonstrates an above-average survival. The therapy administered over 52 cycles led to complete molecular and hematological remission and resulted in 5.3 years overall survival. Clonal evolution of the leukemic clone could be demonstrated using DNA sequencing methods. According to the literature, this case constitutes the longest continued HMA exposure in an elderly AML patient ineligible for standard chemotherapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13148-023-01596-5.
format Online
Article
Text
id pubmed-10683313
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106833132023-11-30 Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics Javorniczky, Nora Rebeka Grishina, Olga Hund, Inga Pantic, Milena Pfeifer, Dietmar Schmoor, Claudia Thomas, Johanna Duyster, Justus Becker, Heiko Lübbert, Michael Clin Epigenetics Brief Report Elderly patients with AML ineligible for induction have a dismal prognosis; hence disease stabilization is a primary treatment goal. This case of a 75-year-old patient with secondary AML receiving the combination of decitabine and ATRA (within the DECIDER trial, NCT00867672) demonstrates an above-average survival. The therapy administered over 52 cycles led to complete molecular and hematological remission and resulted in 5.3 years overall survival. Clonal evolution of the leukemic clone could be demonstrated using DNA sequencing methods. According to the literature, this case constitutes the longest continued HMA exposure in an elderly AML patient ineligible for standard chemotherapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13148-023-01596-5. BioMed Central 2023-11-28 /pmc/articles/PMC10683313/ /pubmed/38012682 http://dx.doi.org/10.1186/s13148-023-01596-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Brief Report
Javorniczky, Nora Rebeka
Grishina, Olga
Hund, Inga
Pantic, Milena
Pfeifer, Dietmar
Schmoor, Claudia
Thomas, Johanna
Duyster, Justus
Becker, Heiko
Lübbert, Michael
Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics
title Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics
title_full Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics
title_fullStr Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics
title_full_unstemmed Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics
title_short Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics
title_sort long-term decitabine/retinoic acid maintenance treatment in an elderly saml patient with high-risk genetics
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683313/
https://www.ncbi.nlm.nih.gov/pubmed/38012682
http://dx.doi.org/10.1186/s13148-023-01596-5
work_keys_str_mv AT javorniczkynorarebeka longtermdecitabineretinoicacidmaintenancetreatmentinanelderlysamlpatientwithhighriskgenetics
AT grishinaolga longtermdecitabineretinoicacidmaintenancetreatmentinanelderlysamlpatientwithhighriskgenetics
AT hundinga longtermdecitabineretinoicacidmaintenancetreatmentinanelderlysamlpatientwithhighriskgenetics
AT panticmilena longtermdecitabineretinoicacidmaintenancetreatmentinanelderlysamlpatientwithhighriskgenetics
AT pfeiferdietmar longtermdecitabineretinoicacidmaintenancetreatmentinanelderlysamlpatientwithhighriskgenetics
AT schmoorclaudia longtermdecitabineretinoicacidmaintenancetreatmentinanelderlysamlpatientwithhighriskgenetics
AT thomasjohanna longtermdecitabineretinoicacidmaintenancetreatmentinanelderlysamlpatientwithhighriskgenetics
AT duysterjustus longtermdecitabineretinoicacidmaintenancetreatmentinanelderlysamlpatientwithhighriskgenetics
AT beckerheiko longtermdecitabineretinoicacidmaintenancetreatmentinanelderlysamlpatientwithhighriskgenetics
AT lubbertmichael longtermdecitabineretinoicacidmaintenancetreatmentinanelderlysamlpatientwithhighriskgenetics

Ejemplares similares